BioCentury
ARTICLE | Clinical News

NGM's NGM282 meets in Phase II data for NASH

April 27, 2018 7:32 PM UTC

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) reported data from a single-blind Phase II trial in 19 non-alcoholic steatohepatitis (NASH) patients showing that once-daily subcutaneous 3 mg NGM282 met the primary endpoint of reducing absolute liver fat content as measured by MRI-proton density fat fraction (PDFF) from baseline to week 12. All 19 patients achieved a reduction in absolute liver fat content of ≥5%, the primary endpoint. Additionally, all 19 patients achieved a reduction in absolute liver fat content of ≥30% from baseline to week 12. Mean changes in absolute and relative liver fat content from baseline to week 12 were 11.2% and 67%, respectively.

Additionally, NGM282 improved fibrosis by ≥1 stage in 42% of patients and by ≥2 stages in 16% of patients at week 12. NGM282 also reduced non-alcoholic fatty liver disease (NAFLD) activity score (NAS) by ≥2 points with at least one point of improvement in either inflammation or ballooning in 58% of patients at week 12...